Hangzhou Fuluo Biological Technology Co.,Ltd.
High quality, competitive price, fast delivery
Payment & Shipping Terms:
|Product Name:||Rimonabant||CAS NO:||168273-06-1|
|Molecular Formula:||C22H21Cl3N4O||Molecular Weight:||463.79|
|Appearance:||A white,Crystalline Powder or colorless crystals|
|Loss on Drying:||≤0.2%|
|Residue on ignition:||≤0.1%|
Rimonabant is a new weight loss drug, not only can lose weight, but also lower blood pressure, cholesterol and blood sugar.
Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.
Rimonabant works by blocking endogenous cannabinoid from binding to neuronal CB1 receptors. The activation of these receptors by endogenous cannabinoids, such as anadamide, increases an individuals appetite. By blocking the activation of the receptors, appetite suppression may occur.
Rimonabant is a receptor (CB1) antagonist, by blocking the brain receptor to decrease the appetite and cravings. That reduces a person's weight while people quit nicotine dependence on cigarettes in order to achieve smoking cessation effect.
The use of rimonabant after one year produces modest weight loss of approximately 5%. Even modest amounts of weight loss may be potentially beneficial. The observed results should be interpreted with some caution, though, since the evaluated studies presented some deficiencies in methodological quality. Studies with longer follow-ups after the end of treatment and of more rigorous quality should be done before definitive recommendations can be made regarding the role of this new medication in the management of overweight or obese patients.
|T3 /Liothyronine sodium/Cytomel||CAS 55-06-1|
|Lorcaserin HCI||CAS 846589-98-8|
|CLA (Conjugated Linoleic Acid)||CAS 2420-56-6|
|Calcium Pyruvate||CAS 52009-14-0|
|Dextromethorphan Hydrobromide||CAS 6700-34-1|
|Lorcaserin hydrochloride||CAS 846589-98-8|